Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010
- PMID: 22276104
- PMCID: PMC3262782
- DOI: 10.1371/journal.pone.0029116
Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010
Abstract
MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A developed for the African "meningitis belt". In Niger, the first two phases of the MenAfriVac introduction campaign were conducted targeting 3,135,942 individuals aged 1 to 29 years in the regions of Tillabéri, Niamey, and Dosso, in September and December 2010. We evaluated the campaign and determined which sub-populations or areas had low levels of vaccination coverage in the regions of Tillabéri and Niamey. After Phase I, conducted in the Filingué district, we estimated coverage using a 30×15 cluster-sampling survey and nested lot quality assurance (LQA) analysis in the clustered samples to identify which subpopulations (defined by age 1-14/15-29 and sex) had unacceptable vaccination coverage (<70%). After Phase II, we used Clustered Lot Quality Assurance Sampling (CLQAS) to assess if any of eight districts in Niamey and Tillabéri had unacceptable vaccination coverage (<75%) and estimated overall coverage. Estimated vaccination coverage was 77.4% (95%CI: 84.6-70.2) as documented by vaccination cards and 85.5% (95% CI: 79.7-91.2) considering verbal history of vaccination for Phase I; 81.5% (95%CI: 86.1-77.0) by card and 93.4% (95% CI: 91.0-95.9) by verbal history for Phase II. Based on vaccination cards, in Filingué, we identified both the male and female adult (age 15-29) subpopulations as not reaching 70% coverage; and we identified three (one in Tillabéri and two in Niamey) out of eight districts as not reaching 75% coverage confirmed by card. Combined use of LQA and cluster sampling was useful to estimate vaccination coverage and to identify pockets with unacceptable levels of coverage (adult population and three districts). Although overall vaccination coverage was satisfactory, we recommend continuing vaccination in the areas or sub-populations with low coverage and reinforcing the social mobilization of the adult population.
Conflict of interest statement
Similar articles
-
From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010 - January 2012.Vaccine. 2013 Mar 15;31(12):1597-603. doi: 10.1016/j.vaccine.2013.01.015. Epub 2013 Jan 19. Vaccine. 2013. PMID: 23337027
-
Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010.Vaccine. 2012 Jul 27;30(35):5229-34. doi: 10.1016/j.vaccine.2012.06.006. Epub 2012 Jun 16. Vaccine. 2012. PMID: 22709955
-
Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination.BMC Infect Dis. 2013 Dec 6;13:576. doi: 10.1186/1471-2334-13-576. BMC Infect Dis. 2013. PMID: 24313998 Free PMC article.
-
An Update on Meningococcal Vaccination.R I Med J (2013). 2020 Aug 3;103(6):41-43. R I Med J (2013). 2020. PMID: 32752565 Review.
-
Serogroup A meningococcal conjugate vaccines in Africa.Expert Rev Vaccines. 2015;14(11):1441-58. doi: 10.1586/14760584.2015.1084232. Epub 2015 Aug 31. Expert Rev Vaccines. 2015. PMID: 26358167 Review.
Cited by
-
Intervene before leaving: clustered lot quality assurance sampling to monitor vaccination coverage at health district level before the end of a yellow fever and measles vaccination campaign in Sierra Leone in 2009.BMC Public Health. 2012 Jun 7;12:415. doi: 10.1186/1471-2458-12-415. BMC Public Health. 2012. PMID: 22676225 Free PMC article.
-
Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S434-41. doi: 10.1093/cid/civ551. Clin Infect Dis. 2015. PMID: 26553672 Free PMC article. Review.
-
Public Health Impact After the Introduction of PsA-TT: The First 4 Years.Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S467-72. doi: 10.1093/cid/civ499. Clin Infect Dis. 2015. PMID: 26553676 Free PMC article.
-
The Long Road to an Effective Vaccine for Meningococcus Group B (MenB).Ann Med Surg (Lond). 2013 Nov 4;2(2):53-6. doi: 10.1016/S2049-0801(13)70037-2. eCollection 2013. Ann Med Surg (Lond). 2013. PMID: 25628885 Free PMC article. Review.
-
Measuring coverage in MNCH: design, implementation, and interpretation challenges associated with tracking vaccination coverage using household surveys.PLoS Med. 2013;10(5):e1001404. doi: 10.1371/journal.pmed.1001404. Epub 2013 May 7. PLoS Med. 2013. PMID: 23667334 Free PMC article. Review.
References
-
- Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg. 1999;93:341–353. - PubMed
-
- World Health Organization (WHO) Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. Wkly Epidemiol Rec. 2010;85:47–63. - PubMed
-
- WHO. Response to epidemic meningitis in Africa, 1997. Wkly Epidemiol Rec. 1997;72:313–318. - PubMed
-
- LaForce FM, Konde K, Viviani S, Preziosi MP. The Meningitis Vaccine Project. Vaccine. 2007;25(Suppl 1):A97–100. S0264-410X(07)00474-4 [pii];10.1016/j.vaccine.2007.04.049 [doi] - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical